Rebecca Forman, MD
Clinical FellowDownloadHi-Res Photo
About
Titles
Clinical Fellow
Appointments
Departments & Organizations
Education & Training
- MD
- Albert Einstein College of Medicine (2019)
- BA
- Yeshiva University, Biology (2015)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Rebecca Forman's published research.
Aarti Bhatia, MD, MPH
Barbara Burtness, MD
Hari Deshpande, MD
Publications
2022
Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients
Forman R, Deshpande H, Burtness B, Bhatia AK. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients. Head & Neck 2022, 44: 1777-1786. PMID: 35488876, DOI: 10.1002/hed.27077.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRECIST response rateProgression-free survivalMetastatic/recurrent diseaseOverall survivalInduction chemotherapyRecurrent diseaseNeck cancerMetastatic/recurrent headPFS/overall survivalMean progression-free survivalSuccessful induction rateMean overall survivalPercent of patientsCases of metastasisFrail subsetWeekly paclitaxelFrail patientsAdult patientsElderly patientsPerformance statusRecurrent headInduction cohortInduction groupPatientsRecurrent group
2021
Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer in elderly or frail patients.
Forman R, Bhatia A, Burtness B. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer in elderly or frail patients. Journal Of Clinical Oncology 2021, 39: 6042-6042. DOI: 10.1200/jco.2021.39.15_suppl.6042.Peer-Reviewed Original ResearchCitationsAltmetricConceptsProgression-free survivalOverall survivalInduction chemotherapyFrail patientsAdverse effectsMean progression-free survivalNeck squamous cell carcinomaP16-positive diseasePrimary end pointRECIST response rateCommon adverse effectsMean overall survivalRetrospective observational studyCommon tumor siteCommon reason patientsSquamous cell carcinomaCases of metastasisDose interruptionWeekly paclitaxelAdvanced diseaseGastrointestinal symptomsMetastatic headPrior radiationChart reviewElderly patients
News
News
- June 01, 2024
Accolades, Awards & Honors
- May 31, 2024
2024 ASCO Conquer Cancer Grants & Awards Announced
- September 15, 2022
Discoveries & Impact (September 2022)